| ²é¿´: 552 | »Ø¸´: 0 | |||
linlin7
|
[½»Á÷]
FDA·ÂÖÆÒ©°ì¹«ÊÒOGDÔÚ»úÖÆÐÔ¿Ú·þÎüÊÕ½¨Ä£ÓëÄ£ÄâµÄ¾ÑéºÍ³É¾Í-Xinyuan Zhang@FDA
|
|
FDA·ÂÖÆÒ©°ì¹«ÊÒOGDÔÚ»úÖÆÐÔ¿Ú·þÎüÊÕ½¨Ä£ÓëÄ£ÄâµÄ¾ÑéºÍ³É¾Í-Xinyuan Zhang@FDA OGD Experience and Efforts on Oral Absorption Modeling and Simulation FDA·ÂÖÆÒ©°ì¹«ÊÒOGDÔÚ»úÖÆÐÔ¿Ú·þÎüÊÕ½¨Ä£ÓëÄ£ÄâµÄ¾ÑéºÍ³É¾Í Xinyuan(Susie) Zhang Office of Generic Drugs µ¼¶Á£º 5ÔÂ19ÈÕ£¬ÃÀ¹úFDA·ÂÖÆÒ©²¿OGD¾Ù°ì¡°¿Ú·þ½¨Ä£ÓëÄ£ÄâÔÚÖÆ¼Á¿ª·¢ÓëBEÆÀ¼ÛÓ¦ÓÃÅàѵ°à¡±£¬ FDA·ÂÖÆÒ©°ì¹«ÊÒXinyuan Zhang²©Ê¿²ûÊöÁËOGDÔÚ»úÖÆÐÔ¿Ú·þÎüÊÕ½¨Ä£ÓëÄ£ÄâµÄ¾ÑéºÍ³É¾Í¡£ Xinyuan Zhang²©Ê¿·ÖÏíÁË£º 1£©·ÂÖÆÒ©°ì¹«ÊÒOGDÔÚÎüÊÕÄ£Ðͽ¨Ä£ÓëÄ£ÄâµÄ½øÕ¹ 2£©Ó¦Óð¸Àý -Evaluate the impact of slow dissolution in a specific pH condition on BE (warfarin sodium tablets) -Evaluate the PPI impact on BE (prasugrel HCl tablets, fingolimod capsules) 3£©GDUFA »ù½ð¶ÔÌá¸ß¿Ú·þÎüÊÕÄ£Ð͵Ľ¨Ä£ÓëÄ£ÄâµÄÓ°Ïì ×ܽ᣺ 1£©OGDÒѾ½«»ùÓÚ»úÖÆÎüÊÕÄ£Ð͵Ľ¨Ä£ÓëÄ£ÄâÄÉÈëµ½³£¹æµÄ·¨¹æ¼à¹Ü»î¶¯ÖÐ 2£©OGDÕý»ý¼«µØ¸ÄÉÆ¹ÌÌå¿Ú·þÖÆ¼ÁÔ¤²â¿ÆÑ§ 3£©OGDÔ¸ÒâÓëÄÚ²¿ºÍÍⲿÀûÒæÏà¹ØÕߺÏ×÷£¬ÔÚÒ©Îï²úÆ·¿ª·¢ºÍ¹ÜÀíÆÀÉóÖдٽø»úÖÆÐÔÎüÊÕÄ£Ð͵Ľ¨Ä£ºÍÄ£ÄâµÄÓ¦ÓᣠXinyuan Zhang ²©Ê¿µÄ²¿·ÖÏà¹ØÎÄÕ¼°Poster 1£©Modeling and Simulation of Biopharmaceutical Performance 2£©The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation 3£©Utility of Physiologically Based Absorption Modeling in Implementing Qualityby Design in Drug Development 4£©Application of Physiologically Based Absorption Modeling forAmphetamine Salts Drug Products in Generic Drug Evaluation 5£©Physiologically Based Absorption Modeling to Study Food Effects for a BCS II Drug 6£©Computational Simulation aided Bioequivalence Study Design for an Antiepileptic Drug ÏÂÔØÔÎļþÇëµã»÷Á´½Ó£ºhttp://pan.baidu.com/s/1miGodg0#rd |
» ²ÂÄãϲ»¶
ÎÒ¾ÍÊÇÉêÇëÒ»¸öÃæÉÏÏîÄ¿¶øÒÑ£¬ÕâÆÀÉóÒâ¼ûÊǰ´ÕÕ½ÜÇàµÄÌõ¼þÆÀµÄ°É£¿
ÒѾÓÐ3È˻ظ´
ÓжàÉÙÈËÊǽñÌì²éϵͳ֪µÀ½á¹ûµÄ£¿
ÒѾÓÐ18È˻ظ´
¹ú×ÔÈ»ÆÀÉóÒâ¼û
ÒѾÓÐ15È˻ظ´
Ϊʲô×ÊÖúÊý¸÷´ó¸ßУ¶¼´´Ð¸ߣ¬×Ô¼ºÉêÇëÔõô¾ÍÕâôÄÑ
ÒѾÓÐ13È˻ظ´
¹ú×ÔÈ»ÃæÉϸ´ÅÌ~»¶ÓÌÖÂÛ
ÒѾÓÐ14È˻ظ´
ϵͳ²é²»µ½
ÒѾÓÐ11È˻ظ´
ÓÐûÓÐÈÔûÊÕµ½ÐÅÏ¢µÄ
ÒѾÓÐ3È˻ظ´
µ¼Ê¦Í²ۣºÎÒÔõô̯ÉÏÁËÕâô¸ö¼«Æ·Ñо¿Éú£¡
ÒѾÓÐ8È˻ظ´
»ù½ð²»ÖУ¬¹²Ãã
ÒѾÓÐ11È˻ظ´
Â鷳ר¼ÒÃÇ¿´¿´ÆÀίÃǵÄÒâ¼û£¨F¿ÚÃæÉÏ£©
ÒѾÓÐ9È˻ظ´










»Ø¸´´ËÂ¥
30